ASX Announcement

OPENS ENROLMENT TO COLLECT DATA FOR AUSTRALIA APPROVAL

Sydney 18 November 2008: Cardiac catheter company CathRx Limited (ASX: CX) today announced the start of a 60-patient clinical trial at Sydney's Westmead hospital aimed at gathering data for Australian Therapeutic Goods Administration (TGA) approval of its range of diagnostic catheters.

Westmead is one of Australia's largest teaching hospitals and a preeminent cardiology centre.

The Principal Investigator for CathRx's Australian approval trial will be Dr Stuart Thomas.

CathRx Chief Executive Officer Neil Anderson said the Australian clinical trial would provide specific Australian clinical performance data in addition to that which it is gaining from sales in Europe.

"The catheters already have CE marking approval for use in Europe but this trial will also allow the feedback from local clinical specialists."

The primary end point for the Australian approval trial is a confirmation of diagnosis capability.

The protocol calls for the use of CathRx's catheter in 30 patients (with 30 control patients) undergoing electrophysiology procedures that require the use of diagnostic catheters.

The data gathered will complement the submissions of a quality system audit and design dossier. This process is similar to the CE marking approval process for Europe.

Cardiac catheters are minimally invasive tools widely used by specialist clinicians to diagnose and treat different types of cardiac arrhythmias.

For further information:

Neil Anderson
CathRx Chief Executive Officer
Ph: 02 9397 5700

Andrew Geddes
Seed Media
Ph: 0408 677 734 or 02 9555 4453

Clinical Trial Reporting

CathRx provides the following information in relation to *Australian Stock Exchange Code of Best Practice for Life Science Companies*.

Name of Trial	CathRx Australian TGA Approval Data Trial
Products	Four electrode and 10 electrode diagnostic catheters with a range of formable and deflectable stylets (small, medium, large or extra large)
Primary end point	Confirmation of diagnosis capability.
Number of subjects	60
Trial design	Randomised 30 test and 30 control
Selection criteria	Patients scheduled for electrophysiology or ablation procedures Over 18 years and English-speaking background Not in emergency care, neo-natal or impaired capacity
Main location of trial	Australia
Expected completion of enrolment date	2nd quarter 2009 calendar year
Expected regulatory submission date	2nd quarter 2009 calendar year

CathRx Limited ACN 089 310 421
5 Parkview Drive Homebush Bay NSW 2127 Australia
Ph: +61 (0)2 9397 5700 Fax: +61 (0)2 9397 5701
www.cathrx.com